Evidence map›Paper›PMID 10340390›Full record

ArticleOncogene1999

Functional localization of a melanoma tumor suppressor gene to a small (< or = 2 Mb) region on 11q23.

G P Robertson, E K Goldberg, T G Lugo, J W Fountain

Abstract read
PubMed Publisher
In one paragraph

Article in Oncogene, 1999. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.5field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 26 citations in OpenAlex.

  1. Article
  2. Molecular clonality of in-transit melanoma metastasis.The American journal of pathology · 2001
    Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 1 country.

G P RobertsonDivision of Biomedical Sciences, University of California, Riverside 92521, USA.
E K Goldberg
T G Lugo
J W Fountain
University of Southern California · USLudwig Cancer Research · USNational Cancer Institute · US

Funding

UNRAVELING THE ROLE OF 9P21 GENE MUTATIONS IN MELANOMAR01CA066021 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI FOUNTAIN, JANE W. · 1995 to 1997
–
CIT NIH HHS CCT0197NCI NIH HHS CA66021
6 · The paper itself

Abstract

We have previously demonstrated the existence of a melanoma tumor suppressor gene(s) on the long arm of chromosome 11 through suppression of tumorigenicity assays. Although loss of heterozygosity studies also support this finding, only a large critical region (44 cM) has been identified to date on 11q22-25. To further localize a tumor suppressor gene(s) within this region, we have now generated and characterized nine melanoma microcell hybrids, each retaining an introduced fragment of 11q. Of the nine hybrids, four were suppressed for tumor formation in nude mice, while five formed tumors at the same rate as the parental melanoma cell line (UACC 903). Molecular analysis of the hybrids with 118 microsatellite markers narrowed the location of a putative suppressor gene to a small (< or =2 Mb) candidate region on 11q23 between the markers D11S1786 and D11S2077 and within the larger region frequently deleted in melanoma tumors and cell lines. While multiple tumor suppressor genes are likely to reside on 11q22-25, the presence of this region in all four suppressed hybrids supports the simplest model that a single locus is responsible for the suppressed phenotype observed in UACC 903.

Indexed as

Chromosomes, Human, Pair 11Genes, Tumor SuppressorAnimalsBase SequenceChromosome MappingDNA PrimersGenetic MarkersHumansIn Situ Hybridization, FluorescenceLoss of HeterozygosityMaleMelanomaMiceMice, NudeMicrosatellite RepeatsMolecular Sequence DataDNA PrimersGenetic Markers

Identifiers

PMID10340390
OpenAlexW2330057121

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.